| Dexrazoxane as a cardioprotectant in children receiving anthracyclines. | |
| | |
MedLine Citation:
|
PMID: 21051660 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Anthracyclines play a critical role in the treatment of a variety of childhood cancers. However, the cumulative cardiotoxic effects of anthracyclines limit the use of these agents in many treatment regimens. Dexrazoxane is a cardioprotectant that significantly reduces the incidence of adverse cardiac events in women with advanced breast cancer treated with doxorubicin-containing regimens. Clinical evidence for the efficacy of dexrazoxane as a cardioprotectant in children, especially from randomized clinical trials, is limited, but the available data support a short-term cardioprotective effect. Long-term follow-up in children treated with dexrazoxane has not been reported. Dexrazoxane's impact on the antitumor effect and toxicity profile of the anthracyclines and the role of dexrazoxane in the development of secondary malignant neoplasms in patients who received dexrazoxane are reviewed. Based on the available data, dexrazoxane appears to be a safe and effective cardioprotectant in children, and it does not appear to alter overall survival times in children with cancer. Continued follow-up from previous trials is needed to determine the long-term effect of dexrazoxane on cardiac outcomes and quality of life. |
| | |
Authors:
|
Dana M Sepe; Jill P Ginsberg; Frank M Balis |
Publication Detail:
|
Type: Journal Article Date: 2010-11-04 |
Journal Detail:
|
Title: The oncologist Volume: 15 ISSN: 1549-490X ISO Abbreviation: Oncologist Publication Date: 2010 |
Date Detail:
|
Created Date: 2010-12-01 Completed Date: 2011-06-07 Revised Date: 2012-09-20 |
Medline Journal Info:
|
Nlm Unique ID: 9607837 Medline TA: Oncologist Country: United States |
Other Details:
|
Languages: eng Pagination: 1220-6 Citation Subset: IM |
Affiliation:
|
Division of Oncology, The Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA. sepe@email.chop.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Anthracyclines / administration & dosage, adverse effects*, therapeutic use Antineoplastic Agents / adverse effects* Arrhythmias, Cardiac / chemically induced*, prevention & control Cardiomyopathies / chemically induced*, prevention & control Cardiotonic Agents / administration & dosage, adverse effects, therapeutic use* Child Child, Preschool Heart Failure / chemically induced*, prevention & control Humans Razoxane / administration & dosage, adverse effects, therapeutic use* Risk Factors Treatment Outcome Young Adult |
| Chemical | |
Reg. No./Substance:
|
0/Anthracyclines; 0/Antineoplastic Agents; 0/Cardiotonic Agents; 21416-87-5/Razoxane |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Fatigue in renal cell carcinoma: the hidden burden of current targeted therapies.
Next Document: Perturbation of cullin deneddylation via conditional Csn8 ablation impairs the ubiquitin-proteasome ...